tradingkey.logo
tradingkey.logo
Search

Rallybio Corp

RLYB
Add to Watchlist
15.815USD
-0.125-0.78%
Close 07/02, 13:00ETQuotes delayed by 15 min
82.90MMarket Cap
LossP/E TTM

TradingKey Stock Score of Rallybio Corp

Currency: USD Updated: 2026-07-02

Key Insights

Rallybio Corp's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 147 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 8.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rallybio Corp's Score

Industry at a Glance

Industry Ranking
147 / 387
Overall Ranking
283 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Rallybio Corp Highlights

StrengthsRisks
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Growing
The company is in a growing phase, with the latest annual income totaling USD 858.00K.
Undervalued
The company’s latest PE is -11.60, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.48M shares, decreasing 10.59% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 323.47K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.90.

Analyst Rating

Based on 1 analysts
Hold
Current Rating
8.000
Target Price
+6.10%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Rallybio Corp?

The TradingKey Stock Score provides a comprehensive assessment of Rallybio Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Rallybio Corp’s performance and outlook.

How do we generate the financial health score of Rallybio Corp?

To generate the financial health score of Rallybio Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Rallybio Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Rallybio Corp.

How do we generate the company valuation score of Rallybio Corp?

To generate the company valuation score of Rallybio Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Rallybio Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Rallybio Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Rallybio Corp.

How do we generate the earnings forecast score of Rallybio Corp?

To calculate the earnings forecast score of Rallybio Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Rallybio Corp’s future.

How do we generate the price momentum score of Rallybio Corp?

When generating the price momentum score for Rallybio Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Rallybio Corp’s prices. A higher score indicates a more stable short-term price trend for Rallybio Corp.

How do we generate the institutional confidence score of Rallybio Corp?

To generate the institutional confidence score of Rallybio Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Rallybio Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Rallybio Corp.

How do we generate the risk management score of Rallybio Corp?

To assess the risk management score of Rallybio Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Rallybio Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Rallybio Corp.